

Name of Journal: *World Journal of Stem Cells*

ESPS Manuscript NO: 35835

Manuscript Type: Minireviews

Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease

Maria Dorobantu, Nicoleta-Monica Popa-Fotea, Mihaela Popa, Iulia Rusu, Miruna Mihaela Micheu

Abstract

Despite optimal interventional and medical therapy, ischemic heart disease (IHD) is still an important cause of morbidity and mortality worldwide. Although not included in standard of care rehabilitation, stem cell therapy (SCT) could be a solution for prompting cardiac regeneration. Multiple studies have been published from the beginning of SCT until now, but overall no unanimous conclusion could be drawn in part due to the lack

Match Overview

- | | | |
|---|--|-----|
| 1 | Crossref 51 words
J. O. Beitnes. "Left ventricular systolic and diastolic function improve after acute myocardial infarction treated with ac | 1% |
| 2 | Internet 26 words
crawled on 13-Oct-2012
trialx.com | <1% |
| 3 | Crossref 21 words
"Monday, 1 September 2008", <i>European Heart Journal</i> , 09/02/2008 | <1% |
| 4 | Internet 16 words
crawled on 09-Jul-2017
journal.frontiersin.org | <1% |
| 5 | Internet 15 words
crawled on 06-Sep-2017
pure.uva.nl | <1% |
| 6 | Crossref 12 words
Case Based Echocardiography, 2011. | <1% |

找到约 41,400 条结果 (用时 0.58 秒)

您是不是要找：[Pursuing meaningful *endpoints* for stem cell therapy assessment in ischemic cardiac disease](#)

Endpoints in stem cell trials in ischemic heart failure - NCBI - NIH

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)

作者：M Banovic - 2015 - 被引用次数：5 - [相关文章](#)

2015年8月29日 - [Endpoints in stem cell trials in ischemic heart failure ... with acute presentation of ischemic heart disease](#) has dramatically improved [1].... Given the specifics of [stem cell](#)-based intervention, phase I trials are not [meaningful](#) in Surrogate endpoint parameters used to [assess](#) the effects of [stem cell therapy](#) ...

Bone Marrow Stem Cells for the Treatment of Ischemic Heart Disease ...

link.springer.com/article/10.1007/s12265-009-9095-8 - [翻译此页](#)

Cell [Therapy](#) Bone Marrow [Stem Cell](#) Chronic Myocardial Infarction [Ischemic Heart](#) 26, 27, 28, 31, 32], and ICM with [end-stage](#) chronic [heart failure](#) (CHF) (Fig.

Heart disease and stem cells publications - Stem Cell Institute

<https://www.cellmedicine.com/heart-disease-and-stem-cells/> - [翻译此页](#)

Publications from pubmed on [heart disease](#) and [stem cells](#). ... mass of regenerative cells allow for the isolation of cells in [therapeutic meaningful](#) amounts in ... Early trials using autologous CSC in patients with [ischemic](#) cardiomyopathy have ... Secondary [endpoints](#) included cardiac structure/function and measures of global ...

Gene therapy and stem cell therapy for cardiovascular diseases today ...

www.nature.com > Home > Archive > Supplements > Vol 4 Supp 4 > Article - [翻译此页](#)

Whether the promise of cardiac and vascular regeneration [therapy](#) will fulfill our of the FREEDOM trial to assess whether gene expression, medical management of ... components ... regenerative cell

找到约 39,500 条结果 (用时 0.39 秒)

您是不是要找：**Pursuing meaningful *endpoints* for stem cell therapy assessment in ischemic cardiac disease**

Use of Mesenchymal Stem Cells for Therapy of Cardiac Disease

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)

作者：V Karantalis - 2015 - 被引用次数：125 - [相关文章](#)

Among the cell types under investigation, adult mesenchymal stem cells (MSCs) ... stem cells are lead candidates for cellular therapy not only for heart disease, but assessment of MSC immunology in humans is The Percutaneous Stem Cell The efficacy end points though were derived only from a comparison of 10 ...

Endpoints in stem cell trials in ischemic heart failure - NCBI - NIH

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)

作者：M Banovic - 2015 - 被引用次数：6 - [相关文章](#)

2015年8月29日 - Endpoints in stem cell trials in ischemic heart failure ... with acute presentation of ischemic heart disease has dramatically improved [1]. Given the specifics of stem cell-based intervention, phase I trials are not meaningful in Surrogate endpoint parameters used to assess the effects of stem cell therapy ...

consensus of the Task Force of the European Society of Cardiology ...

<https://academic.oup.com/eurheartj/.../The-consensus-of-the-Task-Force-of-t...> - [翻译此页](#)

作者：A Mathur - 2017 - 被引用次数：10 - [相关文章](#)

2017年10月14日 - Phase III clinical trials of autologous cell therapy have been launched ... This article does not duplicate the many reviews on stem cells and the heart but ... I to Phase II clinical trials with meaningful intermediate end-points that are most in the treatment of heart failure secondary to ischemic heart disease.



全部 图片 视频 地图 新闻 更多

设置 工具

找到约 37,400 条结果 (用时 0.73 秒)

您是不是要找: Pursuing meaningful **endpoints** for stem cell therapy assessment in ischemic cardiac disease

Use of Mesenchymal Stem Cells for Therapy of Cardiac Disease

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429294/> ▾ 翻译此页

作者: V Karantalis - 2015 - 被引用次数: 137 - 相关文章

In this context, mesenchymal **stem cells** are lead candidates for cellular **therapy** not only for **heart disease**, but multiple diseases characterized by fibrosis. The most important **assessment** of MSC immunology in humans is The Percutaneous **Stem Cell** Injection Delivery Effects on Neomyogenesis (POSEIDON; ...

缺少字词: pursuing

Stem Cell Therapy for Heart Failure - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846071/> ▾ 翻译此页

作者: RE Michler - 2013 - 被引用次数: 19 - 相关文章

One novel evolving **therapeutic** strategy for advanced **ischemic heart disease** is regenerative surgery, the transplantation of immature progenitor **cells** into the to **assess** secondary **endpoints**, it is important to recognize that all-cause mortality, cardiac mortality, and the incidence of recurrent MI were better in **cell therapy** ...

缺少字词: meaningful

Endpoints in stem cell trials in ischemic heart failure - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552990/> ▾ 翻译此页

作者: M Banovic - 2015 - 被引用次数: 6 - 相关文章

2015年8月29日 - Surrogate **endpoints** are generally acceptable to evaluate biologic plausibility and feasibility in these early trials, and to aid in hypothesis development for larger phase III studies. Surrogate endpoint parameters used to **assess** the effects of **stem cell therapy** on survival in chronic **ischemic heart**